Search results
Ozempic linked with lower dementia risk, nicotine use, British study finds - ET HealthWorld | Pharma
The Economic Times· 1 day agoLondon: Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive...
Pfizer along witth Eli Lilly and Novo Nordisk, enroute to develop their second generation weight...
CNBC TV18· 3 days agoPfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into...
Novo’s once-weekly insulin rejected by FDA
BioPharma Dive· 3 days agoThe FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes...
Most patients stop using Wegovy, Ozempic for weight loss within two years, analysis finds - ET...
The Economic Times· 4 days agoLondon: Only one in four U.S. patients prescribed Novo Nordisk's Wegovy or Ozempic for weight loss...
India set to witness obesity pill revolution? As patents near expiry, pharma giants gear up for...
Financial Express· 6 days agoBlockbuster obesity drugs like Ozempic and Wegovy have become a global sensation. Now the Indian...
Pfizer moves forward with once-daily weight loss pill
Clinical Trials Arena· 3 days agoThe weight loss market in pharma is in the midst of a boom. Novo Nordisk currently dominates the...
Pfizer moves forward with once-daily weight loss pill after scrapping earlier version - ETPharma
The Economic Times· 3 days agoThe new drug is part of the second-generation of weight-loss pills, under development by companies...
Sellers of fake Ozempic to face charges in Austrian court - ET HealthWorld | Pharma
The Economic Times· 4 days agoVienna: Austrian prosecutors said they will bring criminal charges against two men accused of...
US FTC to sue drug middlemen over insulin prices, source says - ET HealthWorld
The Economic Times· 3 days agoLondon: The U.S. Federal Trade Commission is planning to sue UnitedHealth, Cigna and CVS Health over...
Vivani to start in-human trial for GLP-1 implant for treating obesity
Medical Device Network· 2 days agoGlobalData estimates that GLP-1 receptor agonist sales for T2D and obesity markets will reach more...